Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 5.46
- Piotroski Score 3.00
- Grade Overweight
- Symbol (IMNM)
- Company Immunome, Inc.
- Price $9.82
- Changes Percentage (4.25%)
- Change $0.4
- Day Low $9.33
- Day High $10.03
- Year High $30.96
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $33.00
- High Stock Price Target $35.00
- Low Stock Price Target $23.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$17.58
- Trailing P/E Ratio -0.86
- Forward P/E Ratio -0.86
- P/E Growth -0.86
- Net Income $-106,806,000
